MKI67 and breast carcinoma: The use of Ki-67 endocrine therapy (ET) response for treatment decision making in early-stage breast cancer across Canada is unclear; therefore, we surveyed Canadian physicians to explore current practice patterns, perceptions, and perceived barriers to its’ use in practice.